Determinants of multidrug-resistant tuberculosis among adults undergoing treatment for tuberculosis in Tigray Region, Ethiopia: a case–control study

IF 3.6 3区医学 Q1 RESPIRATORY SYSTEM

BMJ Open Respiratory Research Pub Date : 2024-05-01 DOI:10.1136/bmjresp-2023-001999

Kidane Zereabruk, Tensay Kahsay, Hiyab Teklemichael, Woldu Aberhe, Abrha Hailay, Guesh Mebrahtom, Gebrewahd Bezabh

{"title":"Determinants of multidrug-resistant tuberculosis among adults undergoing treatment for tuberculosis in Tigray Region, Ethiopia: a case–control study","authors":"Kidane Zereabruk, Tensay Kahsay, Hiyab Teklemichael, Woldu Aberhe, Abrha Hailay, Guesh Mebrahtom, Gebrewahd Bezabh","doi":"10.1136/bmjresp-2023-001999","DOIUrl":null,"url":null,"abstract":"Background Multidrug-resistant tuberculosis is a type of tuberculosis that is resistant to at least the first-line antituberculosis drugs namely, rifampicin and isoniazid. However, most of these studies were limited only to a single hospital. Therefore, this study aimed to identify the determinants of multidrug-resistant tuberculosis among adults undergoing treatment for tuberculosis in the Tigray region of Ethiopia. Methods Hospital-based unmatched case–control study was conducted from 1 April 2019 to 30 June 2019. A simple random sampling method was used to select the required sample size. Variables at a p value less than 0.25 in bivariate analysis were entered into a multivariable analysis to identify the determinant factors of multidrug-resistant tuberculosis. Finally, the level of significance was declared at p<0.05. Results Rural residence (adjusted OR (AOR) 2.54; 95% CI 1.34 to 4.83), HIV (AOR 4.5; 95% CI 1.4 to 14.2), relapse (AOR 3.86; 95% CI 1.98 to 7.5), return after lost follow-up (AOR 6.29; 95% CI 1.64 to 24.2), treatment failure (AOR 5.87; 95% CI 1.39 to 24.8) were among the determinants of multidrug-resistant tuberculosis. Conclusion Rural residence, HIV, relapses, return after lost follow-up and treatment failure were the identified determinant factors of multidrug-resistance tuberculosis. Data are available in a public, open access repository.","PeriodicalId":9048,"journal":{"name":"BMJ Open Respiratory Research","volume":"247 1","pages":""},"PeriodicalIF":3.6000,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMJ Open Respiratory Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1136/bmjresp-2023-001999","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}

引用次数: 0

Abstract

Background Multidrug-resistant tuberculosis is a type of tuberculosis that is resistant to at least the first-line antituberculosis drugs namely, rifampicin and isoniazid. However, most of these studies were limited only to a single hospital. Therefore, this study aimed to identify the determinants of multidrug-resistant tuberculosis among adults undergoing treatment for tuberculosis in the Tigray region of Ethiopia. Methods Hospital-based unmatched case–control study was conducted from 1 April 2019 to 30 June 2019. A simple random sampling method was used to select the required sample size. Variables at a p value less than 0.25 in bivariate analysis were entered into a multivariable analysis to identify the determinant factors of multidrug-resistant tuberculosis. Finally, the level of significance was declared at p<0.05. Results Rural residence (adjusted OR (AOR) 2.54; 95% CI 1.34 to 4.83), HIV (AOR 4.5; 95% CI 1.4 to 14.2), relapse (AOR 3.86; 95% CI 1.98 to 7.5), return after lost follow-up (AOR 6.29; 95% CI 1.64 to 24.2), treatment failure (AOR 5.87; 95% CI 1.39 to 24.8) were among the determinants of multidrug-resistant tuberculosis. Conclusion Rural residence, HIV, relapses, return after lost follow-up and treatment failure were the identified determinant factors of multidrug-resistance tuberculosis. Data are available in a public, open access repository.

查看原文本刊更多论文

埃塞俄比亚提格雷地区接受结核病治疗的成年人中耐多药结核病的决定因素：病例对照研究

背景耐多药结核病是一种至少对一线抗结核药物（即利福平和异烟肼）具有耐药性的结核病。然而，这些研究大多仅限于一家医院。因此，本研究旨在确定埃塞俄比亚提格雷地区接受结核病治疗的成年人中耐多药结核病的决定因素。方法从 2019 年 4 月 1 日至 2019 年 6 月 30 日开展了基于医院的非匹配病例对照研究。研究采用简单随机抽样法选取所需的样本量。将二变量分析中 P 值小于 0.25 的变量纳入多变量分析，以确定耐多药结核病的决定因素。最后，以 P<0.05 为显著性水平。结果农村居住地（调整 OR (AOR) 2.54；95% CI 1.34 至 4.83）、HIV（AOR 4.5；95% CI 1.4 至 14.2）、复发（AOR 3.86；95% CI 1.98 至 7.5）、失去随访后返回（AOR 6.29；95% CI 1.64 至 24.2）、治疗失败（AOR 5.87；95% CI 1.39 至 24.8）是耐多药结核病的决定因素。结论农村居民、艾滋病病毒感染者、复发、失去随访后返回以及治疗失败是耐多药结核病的决定因素。数据可在公开、开放的资料库中查阅。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

BMJ Open Respiratory Research RESPIRATORY SYSTEM-

CiteScore

6.60

自引率

2.40%

发文量

审稿时长

12 weeks

期刊介绍： BMJ Open Respiratory Research is a peer-reviewed, open access journal publishing respiratory and critical care medicine. It is the sister journal to Thorax and co-owned by the British Thoracic Society and BMJ. The journal focuses on robustness of methodology and scientific rigour with less emphasis on novelty or perceived impact. BMJ Open Respiratory Research operates a rapid review process, with continuous publication online, ensuring timely, up-to-date research is available worldwide. The journal publishes review articles and all research study types: Basic science including laboratory based experiments and animal models, Pilot studies or proof of concept, Observational studies, Study protocols, Registries, Clinical trials from phase I to multicentre randomised clinical trials, Systematic reviews and meta-analyses.